Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)

This year has offered no shortage of market-moving headlines shaping investor sentiment. Mixed job reports, new tariffs fueling turbulence in U.S. trade policy, and ongoing uncertainty around Federal Reserve decisions have all contributed to a difficult backdrop for identifying compelling investment opportunities.Fortunately, quarterly disclosures from Wall Street's most seasoned investors provide a window into where the "smart money" is moving. Every quarter, investment firms managing over $100 million are required to file a Form 13F with the Securities and Exchange Commission (SEC). This documentation itemizes which stocks firms bought and sold during the most recent quarter -- offering valuable insight into institutional positioning.One of the more interesting moves that came this quarter was from the Duquesne Family Office, led by billionaire investor Stanley Druckenmiller. According to the firm's second-quarter 13F, Druckenmiller initiated a new position in Viking Therapeutics (NASDAQ: VKTX) -- a pharmaceutical stock that has plummeted by 35% so far in 2025.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool